Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership

1. Regeneron Pharmaceuticals, a leading biotechnology company, has announced a collaboration with Mammoth Biosciences, a biotech firm specializing in CRISPR technology, to advance gene editing capabilities.
2. The partnership aims to leverage Mammoth's proprietary CRISPR platform, which includes the novel CRISPR enzyme Cas14, to develop new gene-editing therapies for various diseases.
3. Regeneron has agreed to pay Mammoth an upfront payment of $40 million, with potential milestone payments of up to $650 million and royalties on future sales.
4. The collaboration will focus on in vivo gene editing, which involves editing genes within the body, as opposed to editing cells outside the body and then reintroducing them.
5. Regeneron is known for its work in genetic research and therapeutic development, including the COVID-19 antibody cocktail REGN-COV2, which received emergency use authorization from the U.S. Food and Drug Administration.
6. Mammoth Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, has been at the forefront of CRISPR technology development, with applications ranging from diagnostics to therapeutics.
7. The partnership between Regeneron and Mammoth Biosciences is expected to accelerate the development of new gene-editing therapies for a range of diseases, potentially revolutionizing the field of genetic medicine.